MarketPulse

cardiac myosin inhibitor

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Cytokinetics Q1 2026 Results Due May 5; MYQORZO® Updates Expected

Cytokinetics will report Q1 2026 earnings May 5, discussing MYQORZO® commercialization and pipeline progress in heart failure treatments.
CYTKearnings reportheart failure
GlobeNewswire Inc.GlobeNewswire Inc.··Cytokinetics, Incorporated

Cytokinetics Launches MYQORZO Following FDA Approval, Guides 2026 Spending

Cytokinetics launches MYQORZO for heart disease post-FDA approval; guides $830-870M spending in 2026 with strong cash position supporting commercial expansion.
SNYBAYRYCYTKFDA approvalclinical trials